Lopirin [Switzerland]

Lopirin [Switzerland] Brand names, Lopirin [Switzerland] Analogs

Lopirin [Switzerland] Brand Names Mixture

No information avaliable

Lopirin [Switzerland] Chemical_Formula

C₉H₁₅NO₃S

Lopirin [Switzerland] RX_link

http://www.rxlist.com/cgi/generic/captop.htm

Lopirin [Switzerland] fda sheet

Lopirin [Switzerland] msds (material safety sheet)

Lopirin_[Switzerland] MSDS

Lopirin [Switzerland] Synthesis Reference

D. W. Cushman, U.S. Pat. 4,046,889 (1977)

Lopirin [Switzerland] Molecular Weight

217.286 g/mol

Lopirin [Switzerland] Melting Point

106^oC

Lopirin [Switzerland] H₂O Solubility

Freely soluble

Lopirin [Switzerland] State

Solid

Lopirin [Switzerland] LogP

0.546

Lopirin [Switzerland] Dosage Forms

Tablet (12.5 mg, 25 mg, 50 mg, or 100 mg)

Lopirin [Switzerland] Indication

For the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.

Lopirin [Switzerland] Pharmacology

Captopril, an angiotensin-converting enzyme (ACE) inhibitor, is used to treat hypertension, congestive heart failure, and renal syndromes such as diabetic nephropathy and scleroderma. The adverse effect and pharmacokinetic limitations of captopril stimulated the development enalapril and subsequent ACE inhibitors.

Lopirin [Switzerland] Absorption

75% without food (the presence of food in the gastrointestinal tract reduces absorption by about 30 to 40 percent).

Lopirin [Switzerland] side effects and Toxicity

Symptoms of overdose include coma, lethargy, low blood pressure, sluggishness, and stomach and intestinal irritation and hyperactivity.

Lopirin [Switzerland] Patient Information

Patients should be advised to immediately report to their physician any signs or symptoms suggesting angioedema (e.g., swelling of face, eyes, lips, tongue, larynx and extremities; difficulty in swallowing or breathing; hoarseness) and to discontinue therapy.

Patients should be told to report promptly any indication of infection (e.g., sore throat, fever),which may be a sign of neutropenia, or of progressive edema which might be related to proteinuria and nephrotic syndrome.

All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician.

Patients should be advised not to use potassium-sparing diuret-ics, potassium supplements or potassium-containing salt substitutes without consulting their physician.

Patients should be warned against interruption or discontinuation of medication unless instructed by the physician.

Heart failure patients on captopril therapy should be cautioned against rapid increases in physical activity.

Patients should be informed that captopril should be taken one hour before meals.

Lopirin [Switzerland] Organisms Affected

Humans and other mammals